Skeletal muscle relaxants: Pharmacodynamics and pharmacokinetics in different patient groups

International Journal of Clinical Practice

Volumn 54, Issue 8, 2000, Pages 526-534

  Booij, Lhdj ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATRACURIUM; BENZYLISOQUINOLINE DERIVATIVE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DOXACURIUM; GLOBULIN; HISTAMINE; MIVACURIUM; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PHENYTOIN; ROCURONIUM; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; VECURONIUM;

ANESTHESIA; BRADYCARDIA; DISORDERS OF ACID BASE BALANCE; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MYOTONIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; TACHYCARDIA;

ADJUVANTS, ANESTHESIA; AGE FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; FEMALE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DEPOLARIZING AGENTS; NEUROMUSCULAR DISEASES; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 0033729492     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Donati F, Meiselman C, Plaud B. Vecuronium neuromuscular blockade at the adductor muscles of the larynx and the adductor pollicis. AnesthesMogy 1999; 74: 833-837.
2. Engbaek J, Roed J. Differential effect of pancuronium at the adductor pollicis, the first dorsal interosseous and the hypothenar muscles. An electromyopgraphic and mechano-myographic dose-response study. Ada Anaesthesiol Scand 1992; 36: 664-669.
3. Katz RL. Neuromuscular effects of d-tubocurarine, edrophonium and neostigmine in man. Anesthesiology 1967; 28: 327-336.
4. Robinson AL, Jerwood DC, Stokes MA. Routine suxamethonium in children: a regional survey of current usage. Anaesthesia 1996; 51: 874-878.
5. Frankville DD, Drummond JC. Hyperkalemia after succinylcholine administration in a patient with closed head injury without paresis. Anesthesiology 1987; 67: 264-266.
6. Minton MD, Grosslight K, Stirt JA et al. Increases in intracranial pressure from succinylcholine: prevention by prior nondepolarising blockade. Anesthesiology 1986; 65: 165-169.
7. Warner LO, Brener DL, Davidson PJ et al. Effects of lidocaine, succinylcholine, and trachéal intubation on intraoccular pressure in children anaesthetized with halothane-nitrous oxide. Anesth Analg 1989; 69: 687-690.
8. Kelly RE, Dinner M, Turner LS et al. Succinylcholine increased intraocular pressure in the human eye with Ihe extraocular muscles detached. Anesthesiology 1993; 79: 948-952.
9. Martyn J, Goldhill DR. Goudsouzian NG. Clinical pharmacology of muscle relaxants in patients with burns. J Clin Pharmacol 1986: 26: 680-685.
10. Jensen ES. Viby-Mogensen J. Plasma cholinesterase and abnormal reaction to succinylcholine: 20 years experience with the Danish Cholinesterase research Unit. Ada Anaesthesia! Scand 1995; 39: 151-156.
11. Vanlinthout LEH, van Egmond J, De Boo T et al. Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anuesth 1992; 69: 29-35.
12. Ritter DM, Rettke SR, Ilstrup DM et al. Effect of plasma cholinesterase activity on the duration of action of succinylcholine in patients with genotypically normal enzyme. Anesth Analg 1988; 67: 1123-1126.
13. Whittaker M, Britten JJ. Phenotyping of individuals sensitive to suxamethonium.r J Anaesth 1987; 59: 1052-1055.
14. Robson N, Robertson I, Whittaker M. Plasma cholinesterase changes in the puerperium. Anaesthesia 1986; 41: 243-249.
15. Collard CD, Baker B W, Johnson D et al. Cumulative reduction in serum cholinesterase following repeated therapeutic plasma exchange. J Clin Anesth 1996; 8: 44-48.
16. Shearer ES, Russell GN. The effect of cardiopulmonary bypass on cholinesterase activity. Anaesthesia 1993; 48: 293-296.
17. Blanloeil Y, Delaroche O, Tequi B et al. Apnée prolongée apres administration au cours d'un choc toxique staphylococcique. Ann Fr Anesth Reanim 1996; 15: 189-191.
18. Smith CE, Donati F, Bevan DR. Effects of succinylcholine at the masseter and adductor pollicis muscle in adults. Anesth Analg 1989; 69: 159162.
19. O'Flynn RP, Shutack JG, Rosenberg H et al. Masseter muscle rigidity and malignant hyperthermia susceptibility in pédiatrie patients. Anesthesiology 1994:80: 1228-1233.
20. VanderSpek AFL, Reynolda PI, Fang WB et al. Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br J Anaesth 1990 ; 64: 21 -27.
21. Shanks CA, Somogyi AA, Triggs EJ. Dose-response and plasma concentration- response relationship of pancuronium in man. Anesthesiology 1979; 51: 111-118.
22. Clarke RSJ, Mirakhur RK. Adverse effects of muscle relaxants. Adv Drug React Toxicol Rev 1994; 13: 23-41.
23. Lien CA, Belmont MR, Abalos A et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1131-1138.
24. Robertson EN, Hull JM, Verbeek AM et al. A comparison of rocuronium and vecuronium: the pharmacodynamic, cardiovascular and intra-ocular effects. Em J Anaesthesiol 1994; IKsuppl 9): 116-121.
25. Wintersteiner O, Dutcher JD. Curare alkaloids from Chondodendron tomentosum. Science 1943; 97: 467-470.
26. Booij LHDJ, Krieg NN, Crul JF. Intradermal histamine releasing effect caused by Org-NC 45. A comparison with pancuronium, metocurine and dtubocurarine. Acta Anaesthesiol Scand 1980; 24: 393-394.
27. North FC, Kettelkamp N, Hirshman CA. Comparison of cutaneous and in vitro histamine release by muscle relaxants. Anesthesiology 1987; 66: 543-546.
28. Stellato C, dePaulis A, Cirillo R el al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Aneslhesiology 1991; 74: 1078-1086.
29. Amaki Y, Waud BE, Waud DR. Atracurium-receptor kinetics: simple behavior from a mixture. Anesth Analg 1985; 64: 777-780.
30. Hughes R, Chappie DJ. The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 1981 ; 53: 31 -44.
31. Belmont MR, Lien CA, Quessy S et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1139-1145.
32. Savarese JJ, Ali HH, Basta SJ el al. The clinical neuromuscular pharmacology of Mivacurium chloride (BW B1090U). Anesthesiology 1988; 68: 723-732.
33. Diefenbach C, Abel M, Rump AFE et al. Changes in plasma cholinesterase activity and mivacurium neuromuscular block in response to normothermic cardiopulmonary bypass. Anesth Analg 1995; 80: 1088-1091.
34. Petersen RS, Bailey PL, Kalameghan R et al. Prolonged neuromuscular block after mivacurium. Anesth Analg 1993; 76: 194-196.
35. Mangar D, Kirchhoff GT, Rose PL et al. Prolonged neuromuscular block after mivacurium in a patient with end-stage renal disease. Anesth Analg 1993; 76: 866-867.
36. Goudsouzian NG, d'Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993; 77: 183-185.
37. Maddineni VR, Mirakhur RK. Prolonged neuromuscular block following mivacurium. Ane.sthesiology 1993; 71: 227-231.
38. Ostergaard D, Jensen FS, Jensen E el al. Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients. Acta Anaesthesiol Scand 1992; 36: 702-706.
39. Basta Si, Savarese JJ, AM HH et al. Clinical pharmacology of doxacurium chloride. Anesthesiology 1988; 69: 478-486.
40. Maddineni VR, Cooper R, Stanley JC et al. Clinical evaluation of doxacurium chloride. Anaesthesia 1992; 47: 554-557.
41. Huu-Lainé FK. Pinto-Scognamiglio W. Activité curarisante du dichlorure de 3.20- bistrimethylammonium 5(-prègnane (malouétine) et de ses stereoisomeres. Arch lut Pharmacodyn Thér 1964; 147: 209-219.
42. Buckelt WR, Hewet CL. Savage DS. Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. J Med Chem 1973; 16: 1116-1124.
43. Appadu BL. Lambert DG. Studies on the interaction of steroidal neuromuscular blocking drugs with cardiac muscarinic receptors. Br J Anaesth 1994; 72: 86-88.
44. Marshall IG, Agoston S, Booij LHDJ et al. Comparison of the cardiovascular actions of Org.NC45 with those produced by other non-depolarizing neuromuscular blocking agents in experimental animals. Br J Anaesth 1980:52: 21S-32S.
45. Robertson EN. Fragen RJ, Booij LHDJ et al. Intradermal histamine release by 3 muscle relaxants. Acta Anaesthesiol Scand 1983; 27: 203205.
46. Krieg N. Crul JF. Booij LHDJ. Relative potency of Org NC45, pancuronium. alcuronium and tubocurarine in anaesthetized man. Br J Anaesth 1980; 52: 783-788.
47. Miller RD, Agoston S, Booij LHDJ et al. The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. ./ Pharmacol Kxp Ther 1978; 207: 539-543.
48. Fancy MR. Morris RB, Miller RD et al. Pharmacokinetics of Org NC45 (Norcuron) in patients with and without renal failure. Br J Anaesth 1981; 53: 1049-1053.
49. Booij LHDJ, Knape JTA. The neuromuscular blocking effect of Org 9426. Anaesthesia 1991:46: 341-343.
50. Huizenga ACT, Vandenbrom RHG, Wierda JMKH el al. Intubating conditions and onset of neuromuscular block of rocuronium (ORG 9426); a comparison with suxamethonium. Acta Anaesthesiol Scand 1992; 36: 463468.
51. Wierda JMKH, de Wit APM. Kuizinga K et al. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. Br J Anaesth 1990; 64: 521-523.
52. Szcnohradszky J, Fisher DM, Segredo V et al. Pharmacokinetics of rocuronium bromide (Org 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 1992; 77: 899-904.
53. McCoy EP, Maddineni VR. Elliot P et al. Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium. Can J Anaesth 1993; 408: 703-708.
54. Shanks CA. The pharmacokinetics of onset and offset of neuromuscular block. Anaesth Pharmacol Rev 1993; 1: 20-33.
55. Booij LHDJ. Muscle relaxants and medical status of the patient. Curr Opin Anaesthesiol 1989; 2: 488-492.
56. Wcstra P. Keulemans GTP. Houwertjes MC et al. Mechanisms underlying the prolonged duration of action of muscle relaxants caused by extrahepatic cholestasis. Br J Anaesth 1981; 53: 217-227.
57. Ono K, Nagano O. Ohta Y et al. Neuromuscular effects of respiratory and metabolic acid-base changes in vitro with and without non-depolarizing muscle relaxants. Anesthesiology 1990; 73: 710-716.
58. Fiacchino F. Gemma M, Bricchi M el al. Sensitivity to curare in patients with upper and lower motor neurone dysfunction. Anaesthesia 1991; 46: 980-982.
59. Peduto VA, Gungii P, Di Martino MR et al. Accidental subarachnoid injection of pancuronium. Anes/h Ana/g 1989; 69: 516-517.
60. Moorthy SS, Hilgenberg JC. Resistance to non-depolarizing muscle relaxants in paretic upper extremities of patients with residual hemiplegia. Anesth Ana/g 1980; 59: 624-627.
61. Greenawalt III, JW. Succinylcholine-induced hyperkalemia 8 weeks after a brief paraplegic episode. Anesth Analg 1992; 75: 294-295.
62. Rosenbaum KJ, Neigh JL, Strobel GE. Sensitivity to non-depolarizing muscle relaxants in amyotrophic lateral sclerosis: report of two cases. Anesthfsiiilogy 1971 ; 35: 638-641.
63. Mitchell MM.Ali HH.Savarese JJ. Myotoniaand neuromuscular blocking agents. Anesthesiology 1978; 49: 44-48.
64. Nightingale P, Healy TEJ, McGuinness K. Dystrophia myotonica and atracurium. A case report. Br J Anaesth 1985; 57: 1131.
65. Boltshauser E, Steinmann B, Meyer A et al. Anaesthesia induced rhabdomyolysis in Duchenne muscular dystrophy. Br J Anaesth 1980: 52: 559.
66. Genever EE. Suxamethonium-induced cardiac arrest in unsuspected pseudohypertrophic muscular dystrophy. Br J Anaesth 1971: 43: 984-986.
67. Ohtani Y, Miike T, Ishitsu T et al. A case of malignant hyperthermia with mitochondrial dysfunction. Brain Dev Jpn 1985; 7: 249-253.
68. Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Br J Anaesth 1982; 54: 529-534.
69. Feldman JM. Cardiac arrest after succinylcholine administration in a pregnant patient recovering from Guillain-Barré syndrome. Anesthesiology 1990:72: 942-944.
70. Reilly M, Hutchinson M. Suxamethonium is eontraindicated in the Guillain-Barré syndrome. J Neurol Neurosurg Psych 1991; 54: 1018-1019.
71. Nilsson E. Meretoja OA. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis. Anesthesiology 1990: 73: 28-32.
72. Eisenkraft JB, Book WJ, Mann SM et al. Resistance to succinylcholine in myasthenia gravis: a dose response study. Anesthesiology 1988; 69: 760-763.
73. Vanlinthout LEH, Robertson EN, Booij LHDJ. Response to suxamethonium during propofol-fentanyl-N,0/O, anaesthesia in a patient with active myasthenia gravis receiving chronic anticholinesterase therapy. Anaesthesia 1994;49: 509-511.
74. Baraka A. Suxamethonium block in the myasthénie palient. Correlation with plasma cholinesterase. Anaesthesia 1992: 47: 217-219.
75. Takamori M, Takahashi M, Yasukawa Y et al. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthénie syndrome. J Neurol Sei 1995; 133: 95-101.
76. Wise RP. A myasthénie syndrome complication in bronchial carcinoma. Br J Anaesth 1962; 17:488.
77. Buzello W. Pollmaecher T. Schluermann D et al. The influence of hypothermie cardiopulmonary bypass on neuromuscular transmission in the absence of muscle relaxants. Anesthesiology 1986; 64: 279-281.
78. Buzello W. Schluermann D, Schindler M et al. Hypothermie cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology 1985; 62: 201-204.
79. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. New EngI J Mal 1979; 301: 409-413.
80. Lambert JJ, Durant NN, Henderson EG. Drug-induced modifications of ionic conductance at the neuromuscular junction. Ann Rev Pharmaeol Toxicol 1983; 23: 505-539.
81. Booij LHDJ, Miller RD, Crul JF. Neostigmine and 4-aminopyridinc antagonism of lincomycin-pancuronium neuromuscular blockade in man. Anesth Ana I g 1978:57: 316-321.
82. Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 1981:55: 148-159.
83. Tempelhoff R. Modica PA, Jellish WS el al. Resistance to atracuriuminduced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990; 71: 665-667.
84. Brandom BW, Stiller RL. Cook DR et al. Pharmacokinetics of atracurium in anaesthetized infants and children. Br J Anaesth 1986; 58: 12101213.
85. Mattco RS, Ornstein E. Schwurt?. AE et al. Pharmacokinetics and pharmacodynamics of Or 9426 in elderly surgical patients. Ane.sthesiology 1991:75: A1065.
86. Lien ÇA, Matteo RS, Ornstein E et al. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg 1991; 73: 39-42.
87. Bell PF, Mirakhur RK, Clarke RSJ. Dose-response studies of atracurium, vecuronium and pancuronium in the elderly. Anesthesia 1989; 44: 925-927.
88. Duvaldestin P, Saada J, Berger JL et al. Pharmacokinetics, pharmacodynamics and dose-response relationships of pancuronium in control and elderly subjects. Anesthesio/ogy 1982; 56: 36-40.
89. Bevan DR, Fiset P, Baiendram P et al. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth 1993; 40: 127-132.
90. Willatts SM. Paralysis for ventilated patients? Yes or no? Intens Crit Care Digest 1985; 4: 9-10.
91. Gooch JL, Suchtya MR, Balbierz JM et al. Prolonged paralysis after treatment with neuromuscular junction blocking agents. Crit Care Med 1991; 19: 1125-1131.
92. Heckmatt JZ, Pitt MC, Kirkham F. Peripheral neuropathy and neuromuscular blockade presenting as prolonged respiratory paralysis following critical illness. Neuropediatrics 1993; 24: 123-125.
93. Helliwell TR, Coakley JH, Wagenmakers AJM et al. Necrotizing myopathy in critically-ill patients. J Pathol 1991; 164: 307-314.
94. Kupfer Y, Namba T, Kaldawi E et al. Prolonged weakness after long-term infusion of vecuronium bromide. Ann Int Med 1992; 117: 484-486.
95. Zochodne DW, Ramsay DA, Saly V et al. Acute necrotizing myopathy intensive care: electrophysiological studies. Muscle Nerve 1994; 17: 285-292.
96. Barohn RJ, Jackson CE, Rogers SJ et al. Prolonged paralysis due to nondepolarising neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994; 17: 647-654.
97. Griffin D, Fairman N, Coursin DB et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal relaxants. Chest 1992; 102: 510-514.
98. Op de Coul AAW, Lambregts PCLA, Koeman J et al. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neural Neurosurg 1985; 887: 17-22.
99. Manthous ÇA, Chatila W. Prolonged weakness after the withdrawal of atracurium. Am J Crit Care Med 1994; 150: 1441-1443.
100. Meyer KC, Prielipp RC, Grossman JE et al. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg 1994; 78: 772-774.
101. Hunter JM. Resistance to non-depolarising neuromuscular blocking agents. Br J Anaesth 1991; 67: 511-514.
102. Dodson BA. Kelly BJ, Braswell LM et al. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: an investigation of the molecular mechanism of prolonged paralysis. Crit Care Med 1995; 23: 815-821.
103. Hogue CW, Ward JM, Itani MS et al. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol 1992; 2: 1326-1331.
104. Maselli RA, Leung C. Analysis of anticholinesterase-induced neuromuscular transmission failure. Muscle Nerve 1993; 16: 548-553.
105. Beemer GH, Bjorksten AR, Dawson PJ et al. Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991; 66: 469-475.
106. Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988; 67: 775-778.